Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

UNITED STATES: Tivicay Approved to Treat HIV-1 Infection


Medscape Medical News (08.12.2013)

The US Food and Drug Administration recently approved a new drug called dolutegravir (brand name Tivicay by GlaxoSmithKline) for the treatment of HIV. Tivicay is an integrase strand transfer inhibitor, which blocks an enzyme that the virus needs to reproduce itself. The drug is in the form of a once-daily pill taken in combination with other antiretrovirals. The drug was approved for use by treatment-naïve adults, adults already using antiretroviral drugs (ART), and youth 12 years and over weighing at least 40 kilograms (88.2 lbs.) who have or have not received ART, but who have never taken an integrase strand transfer inhibitor. The drug was tested for safety and efficacy on 2,539 participants, and results show that Tivicay, when used with other ARTs, was effective in reducing viral loads. Side effects included insomnia and headache hypersensitivity reactions, and abnormal liver function in individuals coinfected with hepatitis C and B.


Copyright © 2013 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

Information in this article was accurate in August 19, 2013. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.